Cowen reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report released on Thursday morning, AnalystRatings.com reports.
“On 8/9, Intec reported 2Q19 with a net loss of ($10M) and ended the period with $21.6M in cash on the balance sheet. Operating expenses are expected to be reduced with the P3 trial in Parkinson’s disease now over. The company is evaluating the data for AP-CD/LD to determine what the next steps may be. While the P3 trial outcome was a disappointment, it’s worth noting that the delivery technology that is the foundation of Intec as a company, did deliver the levodopa as it was supposed to. In addition, there are subgroup data that suggest trial design could be different and potentially have success, in our view. Nonetheless, it’s too early to tell and as we await more clarity, we remain Hold rated.”,” Cowen’s analyst commented.
A number of other equities research analysts also recently commented on the stock. BidaskClub downgraded shares of Krystal Biotech from a buy rating to a hold rating in a research report on Thursday. Guggenheim increased their target price on shares of Krystal Biotech from $48.00 to $73.00 and gave the company a buy rating in a research report on Tuesday, June 25th. ValuEngine downgraded shares of Krystal Biotech from a strong-buy rating to a buy rating in a research report on Friday, August 2nd. Zacks Investment Research downgraded shares of Krystal Biotech from a buy rating to a hold rating in a research report on Wednesday, July 24th. Finally, HC Wainwright increased their target price on shares of Krystal Biotech from $56.00 to $59.00 and gave the company a buy rating in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Krystal Biotech has a consensus rating of Buy and a consensus target price of $59.20.
Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.05). As a group, research analysts forecast that Krystal Biotech will post -1.47 earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of KRYS. Bank of Montreal Can purchased a new position in shares of Krystal Biotech in the 2nd quarter valued at $29,000. Tower Research Capital LLC TRC purchased a new position in shares of Krystal Biotech in the 2nd quarter valued at $72,000. Strs Ohio purchased a new position in shares of Krystal Biotech in the 2nd quarter valued at $92,000. Knott David M grew its position in shares of Krystal Biotech by 145.4% in the 1st quarter. Knott David M now owns 3,686 shares of the company’s stock valued at $121,000 after buying an additional 2,184 shares during the last quarter. Finally, TD Asset Management Inc. purchased a new position in shares of Krystal Biotech in the 1st quarter valued at $268,000. 38.59% of the stock is currently owned by hedge funds and other institutional investors.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.
Featured Article: Correction
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.